Calidi Biotherapeutics to Present RedTail Platform at New York Investment Conference
TL;DR
Calidi Biotherapeutics' CEO presentation at the H.C. Wainwright conference highlights their RedTail platform's potential to deliver competitive advantages in treating metastatic cancers through systemic administration.
Calidi's RedTail platform uses engineered enveloped oncolytic viruses to shield from immune clearance, induce tumor lysis, and deliver genetic medicines to metastatic sites via systemic administration.
Calidi's innovative cancer therapy platform aims to improve treatment outcomes for patients with metastatic diseases, potentially making tomorrow better for those facing high unmet medical needs.
Calidi Biotherapeutics is pioneering systemic delivery of oncolytic viruses to target metastatic cancers, with their lead candidate currently in IND-enabling studies for multiple tumor types.
Found this article helpful?
Share it with your network and spread the knowledge!
Calidi Biotherapeutics Inc. announced that CEO Eric Poma will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York from September 8-10, 2025. The presentation will focus on the company's proprietary RedTail platform, an engineered enveloped oncolytic virus technology designed for systemic administration to target metastatic cancer sites. This technology addresses a fundamental limitation in cancer virotherapy by shielding therapeutic viruses from immune detection, allowing them to reach distant tumor locations throughout the body.
The RedTail platform represents a significant advancement in immuno-oncology by solving one of the major challenges in virotherapy: immune system clearance of therapeutic viruses before they reach tumor sites. By engineering viruses to evade immune detection, Calidi's technology enables systemic delivery to metastatic locations, where it can induce tumor lysis and deliver therapeutic genetic medicines directly to cancer cells. This approach could potentially transform cancer treatment by moving beyond the limitations of localized administration that have constrained previous virotherapy approaches.
Calidi's lead candidate from the RedTail platform is currently in IND-enabling studies targeting non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need. The company's progress comes at a critical time as it advances clinical-stage programs that include both systemic and intratumoral administration approaches for various cancer indications. The availability of an on-demand presentation starting September 5 at 7 a.m. ET provides investors and the medical community with early access to detailed information about Calidi's technology and development progress.
The conference presentation represents an important opportunity for Calidi to demonstrate the potential of its platform technology to address significant challenges in metastatic cancer treatment and position itself within the competitive immuno-oncology landscape. For investors seeking additional information, the company maintains a newsroom at https://ibn.fm/CLDI where updates and developments are regularly posted. This presentation highlights how engineered oncolytic viruses could potentially overcome systemic delivery barriers that have limited previous cancer virotherapy approaches, offering new hope for patients with metastatic disease.
Curated from InvestorBrandNetwork (IBN)
